Aliases & Classifications for Neuritis

Aliases & Descriptions for Neuritis:

Name: Neuritis 12 52 42 14 69
Peripheral Neuritis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1803
MeSH 42 D009443
NCIt 47 C116381
UMLS 69 C0027813

Summaries for Neuritis

MalaCards based summary : Neuritis, also known as peripheral neuritis, is related to motor peripheral neuropathy and choroiditis, and has symptoms including neuralgia and sciatica. An important gene associated with Neuritis is PMP2 (Peripheral Myelin Protein 2), and among its related pathways/superpathways are Cytokine Signaling in Immune system and PAK Pathway. The drugs Methylprednisolone and Prednisolone have been mentioned in the context of this disorder. Affiliated tissues include t cells, testes and eye, and related phenotypes are hematopoietic system and behavior/neurological

Wikipedia : 71 Neuritis /nʊˈraɪtɪs/ or /njʊˈraɪtɪs/ is a general term for inflammation of a nerve or the... more...

Related Diseases for Neuritis

Diseases related to Neuritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 401)
id Related Disease Score Top Affiliating Genes
1 motor peripheral neuropathy 31.3 IFNG IL4 TNF
2 choroiditis 29.8 CCL2 IL1B TNF
3 tuberculosis 29.3 CCL2 IL1B IL4 TNF
4 tularemia 29.1 IFNG IL4 TNF
5 pulmonary tuberculosis 28.7 CCL5 IFNG IL4 TNF
6 rheumatoid arthritis 28.5 CCL2 CCL5 IFNG IL1B IL4 TNF
7 optic neuritis 12.4
8 acute retrobulbar neuritis 12.1
9 brachial plexus neuritis 12.0
10 neuromyelitis optica 11.4
11 parsonage turner syndrome 11.4
12 vestibular neuronitis 11.3
13 amyotrophy, hereditary neuralgic 11.3
14 transverse myelitis 11.1
15 labyrinthitis 11.1
16 optic papillitis 11.1
17 amyotrophic neuralgia 10.9
18 optic nerve disease 10.8
19 flynn-aird syndrome 10.7
20 radiation induced brachial plexopathy 10.7
21 intussusception 10.3 IL1B TNF
22 hereditary type 2 neuropathy 10.3 MPZ PMP22
23 retinitis 10.3
24 rickets due to defect in vitamin d 25-hydroxylation 10.3 MAG MBP MPZ
25 chrna1-related congenital myasthenic syndrome 10.3 MPZ PMP22
26 surfactant metabolism dysfunction, pulmonary, 2 10.3 MPZ PMP22
27 craniorachischisis 10.3 MBP MPZ PMP22
28 hypertonia 10.2 MPZ PMP22
29 charcot-marie-tooth disease, type 1e 10.2 MBP MPZ PMP22
30 potocki-lupski syndrome 10.2 MAG MPZ PMP22
31 dextrocardia 10.2 IL1B MAG TNF
32 tau syndrome 10.2 IL1B TNF
33 stocco dos santos syndrome 10.2 IFNG IL1B TNF
34 amyotrophic lateral sclerosis type 14 10.2 IFNG IL1B TNF
35 trichomalacia 10.2 AQP4 MBP TNF
36 parkinson disease 11 10.2 IFNG IL1B TNF
37 gastric dilatation 10.2 AQP4 MBP TNF
38 senile reticular retinal degeneration 10.2 IFNG IL1B TNF
39 childhood brainstem astrocytoma 10.2 AQP4 MAG MBP
40 rickettsialpox 10.2 IFNG IL1B TNF
41 senile angioma 10.2 MAG MPZ PMP22
42 vps11-related autosomal recessive hypomyelinating leukodystrophy 10.2 CCL5 TNF
43 rift valley fever 10.2 IFNG IL1B TNF
44 persistent mullerian duct syndrome 10.2 MBP MOG TNF
45 classic type lipoma 10.2 IFNG IL1B TNF
46 benign eccrine breast spiradenoma 10.2 IFNG IL1B TNF
47 anterior foramen magnum meningioma 10.2 IFNG IL1B TNF
48 periodontosis 10.1 CXCL10 IFNG TNF
49 vulvar nodular hidradenoma 10.1 IFNG IL1B TNF
50 urea cycle disorder 10.1 AQP4 IL1B MBP

Graphical network of the top 20 diseases related to Neuritis:



Diseases related to Neuritis

Symptoms & Phenotypes for Neuritis

UMLS symptoms related to Neuritis:


neuralgia, sciatica

MGI Mouse Phenotypes related to Neuritis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10 CCL5 CXCL10 IFNG IL1B IL4 MAG
2 behavior/neurological MP:0005386 9.97 AQP4 IFNG MAG MBP MOG MPZ
3 immune system MP:0005387 9.93 AQP4 CCL2 CCL5 CXCL10 IFNG IL1B
4 nervous system MP:0003631 9.73 AQP4 CXCL10 IFNG IL1B IL4 MAG
5 vision/eye MP:0005391 9.17 AQP4 IFNG IL4 MBP MOG PMP22

Drugs & Therapeutics for Neuritis

Drugs for Neuritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 169)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
2
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
3
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
4
Glatiramer Acetate Approved, Investigational Phase 4,Phase 3,Phase 2 147245-92-9 3081884
5
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
6
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2,Early Phase 1 50-02-2 5743
7
Interferon beta-1a Approved, Investigational Phase 4,Phase 3 145258-61-3 6438354
8
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
9
Clofazimine Approved, Investigational Phase 4 2030-63-9 2794
10
Dapsone Approved, Investigational Phase 4 80-08-0 2955
11
Rifampin Approved Phase 4 13292-46-1 5458213 5381226
12
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
13
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
14
Nitric Oxide Approved Phase 4 10102-43-9 145068
15
Prilocaine Approved Phase 4 721-50-6 4906
16
Acetylcholine Approved Phase 4 51-84-3 187
17
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
18
Mycophenolic acid Approved Phase 4 24280-93-1 446541
19
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 1 59-30-3 6037
20
leucovorin Approved, Nutraceutical Phase 4 58-05-9 54575, 6560146 143
21 Adrenocorticotropic Hormone Phase 4,Early Phase 1
22 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
23 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
25 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
26 beta-endorphin Phase 4,Early Phase 1
27 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
28 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
29 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Melanocyte-Stimulating Hormones Phase 4,Early Phase 1
33 Methylprednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1
34 Methylprednisolone Hemisuccinate Phase 4,Phase 3,Phase 2,Phase 1
35 Neuroprotective Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Prednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1
38 Prednisolone hemisuccinate Phase 4,Phase 3,Phase 2,Phase 1
39 Prednisolone phosphate Phase 4,Phase 3,Phase 2,Phase 1
40 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
41 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2
42 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
44 Analgesics Phase 4,Phase 2,Phase 3
45 Topoisomerase Inhibitors Phase 4
46 BB 1101 Phase 4,Phase 1,Phase 2,Early Phase 1
47 Dexamethasone 21-phosphate Phase 4,Phase 1,Phase 2,Early Phase 1
48 Dexamethasone acetate Phase 4,Phase 1,Phase 2,Early Phase 1 1177-87-3
49 HIV Protease Inhibitors Phase 4,Phase 2,Phase 1
50
protease inhibitors Phase 4,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 119)
id Name Status NCT ID Phase
1 A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis Unknown status NCT01838174 Phase 4
2 Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS) Unknown status NCT00910598 Phase 4
3 Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Unknown status NCT02021825 Phase 4
4 Effect of High-Dose Prednisolone (Solu Dacortin®) Treatment on Choroidal and Optic Nerve Head Blood Flow in Humans Completed NCT00312325 Phase 4
5 Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis Completed NCT00179478 Phase 4
6 Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse Completed NCT00753792 Phase 4
7 Dexamethasone & Bupivacaine vs Bupivacaine Alone in Combined Femoral and Sciatic Nerve Block for Perioperative Analgesia in Patients Undergoing Lower Limb Surgeries Completed NCT02576782 Phase 4
8 Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of Age Completed NCT01985997 Phase 4
9 Uniform Multidrug Therapy Regimen for Leprosy Patients Completed NCT00669643 Phase 4
10 Evaluation of Ureteral Patency in the Post-indigo Carmine Era Completed NCT02677623 Phase 4
11 Study to Evaluate the Efficacy of Botulinum Toxin Serotype A Injections for Cervicobrachial Myofascial Syndrome Completed NCT00241215 Phase 4
12 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4
13 Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Enrolling by invitation NCT02809079 Phase 4
14 Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis Terminated NCT00854750 Phase 4
15 Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event. Withdrawn NCT00037115 Phase 4
16 A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a Withdrawn NCT00771043 Phase 4
17 The Efficacy of Steroid Therapy in Vestibular Neuritis Unknown status NCT02098330 Phase 3
18 Simvastatin Treatment of Patients With Acute Optic Neuritis Unknown status NCT00261326 Phase 3
19 Optic Neuritis Treatment Trial (ONTT) Unknown status NCT00000146 Phase 3
20 Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone Unknown status NCT00004645 Phase 3
21 Optic Neuritis Recovery After Oral or IV Corticosteroids Completed NCT01524250 Phase 2, Phase 3
22 A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon) Completed NCT00856635 Phase 3
23 Ampyra for Optic Neuritis in MS Completed NCT01337986 Phase 2, Phase 3
24 Intravenous Immunoglobulin Therapy in Optic Neuritis Completed NCT00000117 Phase 3
25 Additional 6-Month Safety Follow-up After Completion of Precursor Study 880801 Completed NCT01604746 Phase 3
26 Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy Completed NCT00666263 Phase 3
27 Hypoalgesic Effect of Neural Mobilization Versus Ibuprofen Pharmacologic Treatment Completed NCT02593721 Phase 2, Phase 3
28 Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Multifocal Motor Neuropathy. Completed NCT01827072 Phase 3
29 Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients Completed NCT03002038 Phase 2, Phase 3
30 Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial Recruiting NCT01962571 Phase 3
31 Erythropoietin in Methanol Associated Optic Neuropathy: A Phase-2 Clinical Trial (EPO-MAON Study) Recruiting NCT02376881 Phase 3
32 A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study) Recruiting NCT01892345 Phase 3
33 Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD Recruiting NCT02073279 Phase 3
34 Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSD Recruiting NCT02028884 Phase 3
35 A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders Recruiting NCT02200770 Phase 2, Phase 3
36 Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis Active, not recruiting NCT02220244 Phase 3
37 An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients Enrolling by invitation NCT02003144 Phase 3
38 MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study) Terminated NCT01647880 Phase 2, Phase 3
39 A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis Terminated NCT02398994 Phase 3
40 Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple Sclerosis Withdrawn NCT01337427 Phase 3
41 Effect of Vitamin D on Retinal Changes in Patient With Optic Neuritis by Optic Coherence Tomography Unknown status NCT01465893 Phase 2
42 Amiloride Clinical Trial In Optic Neuritis Unknown status NCT01802489 Phase 2
43 Amiloride Hydrochlorothiazide as Treatment of Acute Inflammation of the Optic Nerve Unknown status NCT01879527 Phase 2
44 Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica Unknown status NCT01364246 Phase 1, Phase 2
45 AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis Unknown status NCT01228396 Phase 2
46 Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders Unknown status NCT02249676 Phase 2
47 BIIB033 In Acute Optic Neuritis (AON) Completed NCT01721161 Phase 2
48 Safety and Efficacy Study of Erythropoietin as add-on Therapy of Methylprednisolone to Treat Acute Optic Neuritis Completed NCT00355095 Phase 2
49 Neuroprotection With Phenytoin in Optic Neuritis Completed NCT01451593 Phase 2
50 Visual Reconstitution Therapy After Optic Neuritis Completed NCT01274702 Phase 2

Search NIH Clinical Center for Neuritis

Cochrane evidence based reviews: neuritis

Genetic Tests for Neuritis

Anatomical Context for Neuritis

MalaCards organs/tissues related to Neuritis:

39
T Cells, Testes, Eye, Brain, Bone, Pituitary, B Cells

Publications for Neuritis

Articles related to Neuritis:

(show top 50) (show all 1056)
id Title Authors Year
1
Retinal segmented layers with strong aquaporin-4 expression suffered more injuries in neuromyelitis optica spectrum disorders compared with optic neuritis with aquaporin-4 antibody seronegativity detected by optical coherence tomography. ( 28057643 )
2017
2
A Functional and Neuropathological Testing Paradigm Reveals New Disability-Based Parameters and Histological Features for P0180-190-Induced Experimental Autoimmune Neuritis in C57BL/6 Mice. ( 28082327 )
2017
3
Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration. ( 27844165 )
2017
4
Optic neuritis: the eye as a window to the brain. ( 27906756 )
2017
5
Neuroprotection and visual function after optic neuritis. ( 27941524 )
2017
6
Attenuation of experimental autoimmune neuritis with locally administered lovastatin-encapsulating poly(lactic-co-glycolic) acid nanoparticles. ( 27861905 )
2017
7
Transorbital Sonography and Visual Outcome for the Diagnosis and Monitoring of Optic Neuritis. ( 27862614 )
2017
8
Adding Papillomacular Bundle Measurements to Standard Optical Coherence Tomography Does Not Increase Sensitivity to Detect Prior Optic Neuritis in Patients with Multiple Sclerosis. ( 27171375 )
2016
9
Optic neuritis: a 5-year follow-up study of Chinese patients based on aquaporin-4 antibody status and ages. ( 27159992 )
2016
10
Anti-myelin Oligodendrocyte Glycoprotein Antibodies in a Patient with Recurrent Optic Neuritis Involving the Cerebral White Matter and Brainstem. ( 27181546 )
2016
11
Dimethyl fumarate attenuates experimental autoimmune neuritis through the nuclear factor erythroid-derived 2-related factor 2/hemoxygenase-1 pathway by altering the balance of M1/M2 macrophages. ( 27142843 )
2016
12
Aspects of cerebral plasticity related to clinical features in acute vestibular neuritis: a "starting point" review from neuroimaging studies. ( 27196070 )
2016
13
A case of multiple evanescent white dot syndrome misdiagnosed as optic neuritis: Differential diagnosis for the neurologist. ( 27114663 )
2016
14
Optic neuritis secondary to antiandrogen therapy. ( 28039596 )
2016
15
Brachial neuritis or Parsonage-Turner syndrome: A problem of liability. A presentation of 3 cases. ( 26948383 )
2016
16
Case-centered Analysis of Optic Neuritis After Vaccines. ( 27069066 )
2016
17
Pediatric Optic Neuritis Prospective Outcomes Study. ( 27176554 )
2016
18
Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. ( 26163068 )
2016
19
Optic neuritis as an initial presentation of primary SjAPgren syndrome: A case report and literature review. ( 27858858 )
2016
20
Activation of the adenosine A2A receptor exacerbates experimental autoimmune neuritis in Lewis rats in association with enhanced humoral immunity. ( 27049573 )
2016
21
Eleven episodes of recurrent optic neuritis of the same eye for 22 years eventually diagnosed as neuromyelitis optica spectrum disorder. ( 27919493 )
2016
22
Ultrasonic Elastography Evaluation in Optic Neuritis. ( 27628306 )
2016
23
Distinguishing ischaemic optic neuropathy from optic neuritis by ganglion cell analysis. ( 27364519 )
2016
24
A connection between neurovascular conflicts within the cerebellopontine angle and vestibular neuritis, a case controlled cohort study. ( 27958603 )
2016
25
Serial Diffusion Tensor Imaging of the Optic Radiations after Acute Optic Neuritis. ( 27555964 )
2016
26
Optic Neuritis in a Patient with Bickerstaff's Brainstem Encephalitis. ( 27486938 )
2016
27
Pseudo-subarachnoid hemorrhage and optic neuritis in an 18-year-old girl with sodium valproate overdose. ( 27904589 )
2016
28
Unilateral Optic Neuritis: A Rare Complication after Measles-Mumps-Rubella Vaccination in a 30-Year-Old Woman. ( 27195163 )
2016
29
Valproic acid and ASK1 deficiency ameliorate optic neuritis and neurodegeneration in an animal model of multiple sclerosis. ( 28040492 )
2016
30
A prospective cohort study of vitamin D in optic neuritis recovery. ( 27037181 )
2016
31
Alveolar rhabdomyosarcoma of the sphenoid sinus mimicking optic neuritis presenting with intermittent visual loss in an adult. ( 27932889 )
2016
32
Optic neuritis in multiple sclerosis: Looking from a patient's eyes. ( 27432178 )
2016
33
RAD001 (everolimus) attenuates experimental autoimmune neuritis by inhibiting the mTOR pathway, elevating Akt activity and polarizing M2 macrophages. ( 27063582 )
2016
34
Cortical functional modifications following optic neuritis. ( 27207448 )
2016
35
Usefulness of optical coherence tomography to distinguish optic neuritis associated with AQP4 or MOG in neuromyelitis optica spectrum disorders. ( 27582898 )
2016
36
Progressive Loss of Retinal Ganglion Cells and Axons in Nonoptic Neuritis Eyes in Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study. ( 27127930 )
2016
37
Recovery from optic neuritis attack in neuromyelitis optica spectrum disorder and multiple sclerosis. ( 27423624 )
2016
38
20/40 or Better Visual Acuity After Optic Neuritis: Not as Good as We Once Thought? ( 27472185 )
2016
39
Structural Alterations of Segmented Macular Inner Layers in Aquaporin4-Antibody-Positive Optic Neuritis Patients in a Chinese Population. ( 27336477 )
2016
40
Optic neuritis with secondary retinal venous stasis in a case of abdominal tuberculosis. ( 27843238 )
2016
41
Recurrent optic neuritis and neuromyelitis optica-IgG following first and second human papillomavirus vaccinations. ( 27046292 )
2016
42
Insulin neuritis or treatment-induced diabetic neuropathy of diabetes. ( 27474367 )
2016
43
Retinal ganglion cell and axonal loss in optic neuritis: risk factors and visual functions. ( 27858936 )
2016
44
Vitamin D status is negatively correlated with retinal nerve fiber layer thickness in relapsing-remitting MS patients without acute optic neuritis. ( 27301383 )
2016
45
Optic neuritis with TNF alpha antagonists. ( 27213191 )
2016
46
Clinical Reasoning: Left hemiparesis, ataxia, and optic neuritis in a child previously treated for pineoblastoma. ( 27163667 )
2016
47
Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica. ( 27049558 )
2016
48
Resolvin D1 Programs Inflammation Resolution by Increasing TGF-I^ Expression Induced by Dying Cell Clearance in Experimental Autoimmune Neuritis. ( 27629711 )
2016
49
Occurrence of Optic Neuritis and Cervical Cord Schwannoma with Charcot-Marie-Tooth Type 4B1 Disease. ( 27162595 )
2016
50
Combined brain and anterior visual pathways' MRIs assist in early identification of neuromyelitis optica spectrum disorder at onset of optic neuritis. ( 27804015 )
2016

Variations for Neuritis

Expression for Neuritis

Search GEO for disease gene expression data for Neuritis.

Pathways for Neuritis

Pathways related to Neuritis according to GeneCards Suite gene sharing:

(show all 47)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.3 CCL2 CCL5 CXCL10 IFNG IL1B IL4
2
Show member pathways
13.23 CCL2 CCL5 CXCL10 IL1B IL4 TNF
3
Show member pathways
12.85 CCL2 CCL5 CXCL10 IFNG IL1B TNF
4
Show member pathways
12.75 CCL2 CCL5 CXCL10 IFNG IL1B IL4
5
Show member pathways
12.68 CCL5 CXCL10 IFNG IL1B TNF
6
Show member pathways
12.54 IFNG IL1B IL4 TNF
7
Show member pathways
12.53 CCL2 IFNG IL1B TNF
8
Show member pathways
12.37 IFNG IL1B IL4 TNF
9 12.3 CCL2 CCL5 CXCL10 IFNG IL1B IL4
10
Show member pathways
12.24 CCL2 CCL5 IFNG IL1B IL4 TNF
11
Show member pathways
12.21 IFNG IL1B IL4 TNF
12
Show member pathways
12.21 CCL2 CXCL10 IFNG IL1B IL4 TNF
13
Show member pathways
12.16 CXCL10 IFNG IL1B IL4 TNF
14
Show member pathways
12.11 IFNG IL1B IL4 TNF
15 12.06 CCL2 IFNG IL1B TNF
16
Show member pathways
11.97 CCL2 CCL5 CXCL10
17 11.94 IFNG IL4 TNF
18 11.94 CCL2 IL1B IL4 TNF
19 11.93 CCL2 CCL5 CXCL10 IL1B TNF
20
Show member pathways
11.92 IFNG IL1B IL4
21
Show member pathways
11.89 IFNG IL1B TNF
22 11.86 MBP MPZ PMP22
23
Show member pathways
11.86 IFNG IL1B IL4
24 11.84 CCL2 IL1B TNF
25 11.83 IL1B IL4 TNF
26 11.82 IFNG IL1B TNF
27 11.77 IFNG IL1B IL4 TNF
28
Show member pathways
11.72 IFNG IL4 TNF
29 11.72 CCL2 CCL5 IFNG IL1B TNF
30 11.71 IFNG IL1B TNF
31
Show member pathways
11.62 IFNG IL1B TNF
32 11.53 CCL2 IFNG IL1B TNF
33 11.51 CCL2 IFNG IL1B TNF
34 11.49 IFNG IL1B TNF
35 11.45 IFNG IL1B TNF
36 11.36 CXCL10 IFNG IL1B
37 11.36 AQP4 CCL2 CXCL10 IFNG IL1B IL4
38 11.35 CCL2 CCL5 IL1B IL4 TNF
39 11.33 IFNG IL1B TNF
40 11.28 IFNG IL1B IL4 TNF
41 11.23 IFNG IL1B IL4 TNF
42 11.15 CCL2 IFNG IL1B
43 11.12 CCL2 CCL5 CXCL10 IL1B IL4 TNF
44 11.03 CCL2 CCL5 CXCL10 IL1B IL4 TNF
45 10.94 CCL2 IL1B TNF
46 10.86 IL1B IL4
47 10.55 MAG MBP

GO Terms for Neuritis

Cellular components related to Neuritis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.8 CCL2 CCL5 CXCL10 IFNG IL1B IL4
2 myelin sheath GO:0043209 9.26 MAG MBP MPZ PMP2
3 compact myelin GO:0043218 9.16 MAG PMP22
4 external side of plasma membrane GO:0009897 9.02 AQP4 CXCL10 IFNG IL4 TNF

Biological processes related to Neuritis according to GeneCards Suite gene sharing:

(show all 44)
id Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.92 CCL2 CCL5 IL1B MBP TNF
2 chemotaxis GO:0006935 9.88 CCL2 CCL5 CXCL10 IL4
3 response to ethanol GO:0045471 9.87 CCL2 IL4 MT-ND4
4 positive regulation of protein phosphorylation GO:0001934 9.87 IFNG IL1B IL4 TNF
5 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.86 IL1B IL4 TNF
6 cellular response to lipopolysaccharide GO:0071222 9.86 CCL2 CXCL10 IFNG TNF
7 response to virus GO:0009615 9.84 CCL5 CXCL10 IFNG TNF
8 chemokine-mediated signaling pathway GO:0070098 9.83 CCL2 CCL5 CXCL10
9 cell chemotaxis GO:0060326 9.82 CCL2 CCL5 CXCL10
10 cellular response to interferon-gamma GO:0071346 9.81 AQP4 CCL2 CCL5
11 humoral immune response GO:0006959 9.8 CCL2 IFNG TNF
12 myelination GO:0042552 9.79 MBP MPZ PMP22
13 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.79 CCL5 IFNG IL4
14 cellular response to organic cyclic compound GO:0071407 9.78 CCL2 CCL5 IL1B TNF
15 regulation of insulin secretion GO:0050796 9.76 CCL5 IFNG IL1B TNF
16 positive regulation of nitric oxide biosynthetic process GO:0045429 9.75 IFNG IL1B TNF
17 neutrophil chemotaxis GO:0030593 9.73 CCL2 CCL5 IFNG IL1B
18 positive regulation of T cell proliferation GO:0042102 9.71 CCL5 IFNG IL1B IL4
19 negative regulation of lipid catabolic process GO:0050995 9.69 IL1B TNF
20 negative regulation of growth of symbiont in host GO:0044130 9.69 IFNG TNF
21 positive regulation of monocyte chemotaxis GO:0090026 9.69 CCL2 CCL5 CXCL10
22 positive regulation of macrophage chemotaxis GO:0010759 9.68 CCL2 CCL5
23 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.68 IL1B TNF
24 macrophage chemotaxis GO:0048246 9.68 CCL2 CCL5
25 positive regulation of T cell migration GO:2000406 9.67 CCL5 CXCL10
26 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.67 IL1B TNF
27 positive regulation of isotype switching to IgG isotypes GO:0048304 9.67 IFNG IL4
28 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.67 IFNG IL1B TNF
29 positive regulation of cell adhesion GO:0045785 9.67 CCL2 CCL5 IFNG TNF
30 cell-cell adhesion via plasma-membrane adhesion molecules GO:0098742 9.66 MAG MPZ
31 positive regulation of interleukin-6 biosynthetic process GO:0045410 9.65 IFNG IL1B
32 regulation of defense response to virus by host GO:0050691 9.65 IFNG IL1B
33 positive regulation of MHC class II biosynthetic process GO:0045348 9.65 IFNG IL4
34 regulation of establishment of endothelial barrier GO:1903140 9.64 IL1B TNF
35 positive regulation of fever generation GO:0031622 9.62 IL1B TNF
36 protein kinase B signaling GO:0043491 9.62 CCL2 CCL5 IL1B TNF
37 sequestering of triglyceride GO:0030730 9.6 IL1B TNF
38 positive regulation of mononuclear cell migration GO:0071677 9.59 IL4 TNF
39 lipopolysaccharide-mediated signaling pathway GO:0031663 9.56 CCL2 CCL5 IL1B TNF
40 immune response GO:0006955 9.56 CCL2 CCL5 CXCL10 IFNG IL1B IL4
41 positive regulation of vitamin D biosynthetic process GO:0060557 9.55 IFNG TNF
42 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.33 IFNG IL1B TNF
43 positive regulation of chemokine biosynthetic process GO:0045080 8.92 IFNG IL1B IL4 TNF
44 inflammatory response GO:0006954 10 CCL2 CCL5 CXCL10 IL1B TNF

Molecular functions related to Neuritis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.17 CCL2 CCL5 CXCL10 IFNG IL1B IL4
2 chemokine activity GO:0008009 9.13 CCL2 CCL5 CXCL10

Sources for Neuritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....